Could less radiation be just as good for lymphoma?
NCT ID NCT03681535
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study is testing whether a lower dose of radiation (20 Gy instead of 30 Gy) can still control diffuse large B-cell lymphoma in patients who had a good response to chemotherapy. About 241 participants will receive the reduced radiation to see if it keeps the cancer from coming back while causing fewer side effects. The goal is to maintain high local control rates with less toxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy
What this could lead to
If successful, this could mean that many lymphoma patients can receive a lower, safer dose of radiation without compromising cancer control.
What could go wrong
This is a mid-stage study with 241 participants, so results are not yet confirmed. Lower radiation might not control the cancer as well as the standard dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
Weymouth, Massachusetts, 02190, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Juntendo University
Tokyo, Japan
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
National Cancer Center of Singapore
Singapore, Singapore
-
University Hospital Motol
Prague, Czechia
-
University of Rochester James P. Wilmot Cancer Institute
Rochester, New York, 14642, United States
-
University of Torino
Torino, Italy
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yonsei University Health System
Seoul, South Korea